Table 3.

Sleep duration and incidence of ESKD in 1601 patients with CKD

Sleep Duration (h)NRI (95% CI)
of Sleep Duration
≤5.05.1–6.06.1–7.07.1–8.0≥8.0
Number152300541420188
Incidence of ESKD, N (%)29 (19)43 (14)82 (15)83 (20)45 (24)
Incidence rate (per person-year)0.0570.0410.0430.0580.073
Adjusted hazard ratio (95% CI)
 Model 11.29 (0.85 to 1.97)0.98 (0.68 to 1.42)1.00 (reference)1.31 (0.96 to 1.78)1.70 (1.17 to 2.47)a0.10 (0.02 to 0.18)a
 Model 22.21 (1.44 to 3.39)a0.98 (0.67 to 1.43)1.00 (reference)1.20 (0.88 to 1.63)1.54 (1.06 to 2.24)a0.15 (0.02 to 0.28)a
 Model 32.27 (1.48 to 3.50)a1.01 (0.70 to 1.48)1.00 (reference)1.24 (0.91 to 1.69)1.56 (1.07 to 2.27)a0.15 (0.05 to 0.26)a
 Model 4b,c2.05 (1.31 to 3.21)a0.98 (0.67 to 1.44)1.00 (reference)1.22 (0.89 to 1.66)1.48 (1.01 to 2.16)a0.12 (0.02 to 0.26)a
  • Model 1 adjusted for age (yr) and sex. Model 2 adjusted for the covariates in model 1, eGFR (ml/min per 1.73 m2), and urinary albumin excretion (log g/gCr). Model 3 adjusted for the covariates in model 2, smoking status (non-, past, or current smoker), body mass index (kg/m2), history of diabetes mellitus and cardiovascular disease, systolic BP (mm Hg), and blockade of renin-angiotensin system. Model 4 adjusted for the covariates in model 3 and Beck depression inventory score (≤10 and >10) and use of hypnotics (none, 1–2 times, or ≥3 times per wk). NRI, net reclassification index; 95% CI, 95% confidence interval; Cr, creatinine.

  • a P<0.05.

  • b P for interaction of sleep duration with age, sex, history of diabetes and cardiovascular disease, and use of hypnotics=0.79, 0.47, 0.67, 0.49, and 0.78, respectively.

  • c Multivariable-adjusted hazard ratio (95% CI) for none, 1–2 times, and ≥3 times per week use of hypnotics: 1.00 (reference), 0.72 (0.29 to 1.78), and 1.05 (0.71 to 1.56), respectively.